FDA Rejects Treatment Pitched By MyPillow Nutbag

CNN reports:

The FDA has rejected a submission from Phoenix Biotechnology Inc. to market oleandrin as a dietary supplement ingredient, citing “significant concerns” about the safety evidence the company presented.

Last month, MyPillow CEO Mike Lindell, who recently joined the board of Phoenix Biotechnology and has a financial stake in the company, said he had participated in a July meeting at the White House with President Donald Trump regarding the use of oleandrin as a potential therapeutic for the coronavirus.

The extract comes from the Nerium oleander plant; the raw oleander plant is highly toxic and consuming it can be fatal. There are no peer-reviewed, published studies on the impact of oleandrin on Covid-19, and there’s no public evidence it has been studied in patients with Covid-19.